161 related articles for article (PubMed ID: 9371335)
1. In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates.
Chong KT; Pagano PJ
Antimicrob Agents Chemother; 1997 Nov; 41(11):2367-73. PubMed ID: 9371335
[TBL] [Abstract][Full Text] [Related]
2. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor.
Poppe SM; Slade DE; Chong KT; Hinshaw RR; Pagano PJ; Markowitz M; Ho DD; Mo H; Gorman RR; Dueweke TJ; Thaisrivongs S; Tarpley WG
Antimicrob Agents Chemother; 1997 May; 41(5):1058-63. PubMed ID: 9145869
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors.
Rusconi S; La Seta Catamancio S; Citterio P; Kurtagic S; Violin M; Balotta C; Moroni M; Galli M; d'Arminio-Monforte A
Antimicrob Agents Chemother; 2000 May; 44(5):1328-32. PubMed ID: 10770770
[TBL] [Abstract][Full Text] [Related]
4. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.
Cahn P; Villacian J; Lazzarin A; Katlama C; Grinsztejn B; Arasteh K; López P; Clumeck N; Gerstoft J; Stavrianeas N; Moreno S; Antunes F; Neubacher D; Mayers D
Clin Infect Dis; 2006 Nov; 43(10):1347-56. PubMed ID: 17051504
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.
Gathe J; Cooper DA; Farthing C; Jayaweera D; Norris D; Pierone G; Steinhart CR; Trottier B; Walmsley SL; Workman C; Mukwaya G; Kohlbrenner V; Dohnanyi C; McCallister S; Mayers D;
Clin Infect Dis; 2006 Nov; 43(10):1337-46. PubMed ID: 17051503
[TBL] [Abstract][Full Text] [Related]
6. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
[TBL] [Abstract][Full Text] [Related]
7. Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates.
Bulgheroni E; Citterio P; Croce F; Lo Cicero M; Viganò O; Soster F; Chou TC; Galli M; Rusconi S
J Antimicrob Chemother; 2004 Mar; 53(3):464-8. PubMed ID: 14963061
[TBL] [Abstract][Full Text] [Related]
8. Tipranavir: PNU 140690, tipranivir.
Drugs R D; 2006; 7(1):55-62. PubMed ID: 16620137
[TBL] [Abstract][Full Text] [Related]
9. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents.
Robinson BS; Riccardi KA; Gong YF; Guo Q; Stock DA; Blair WS; Terry BJ; Deminie CA; Djang F; Colonno RJ; Lin PF
Antimicrob Agents Chemother; 2000 Aug; 44(8):2093-9. PubMed ID: 10898681
[TBL] [Abstract][Full Text] [Related]
10. Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).
Arribas JR
Curr Opin HIV AIDS; 2009 Nov; 4(6):507-12. PubMed ID: 20048718
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir.
Vourvahis M; Kashuba AD
Pharmacotherapy; 2007 Jun; 27(6):888-909. PubMed ID: 17542771
[TBL] [Abstract][Full Text] [Related]
12. A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
Amano M; Koh Y; Das D; Li J; Leschenko S; Wang YF; Boross PI; Weber IT; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2007 Jun; 51(6):2143-55. PubMed ID: 17371811
[TBL] [Abstract][Full Text] [Related]
13. Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class.
Turner SR; Strohbach JW; Tommasi RA; Aristoff PA; Johnson PD; Skulnick HI; Dolak LA; Seest EP; Tomich PK; Bohanon MJ; Horng MM; Lynn JC; Chong KT; Hinshaw RR; Watenpaugh KD; Janakiraman MN; Thaisrivongs S
J Med Chem; 1998 Aug; 41(18):3467-76. PubMed ID: 9719600
[TBL] [Abstract][Full Text] [Related]
14. Estimated extent of cross-resistance to ritonavir-boosted protease inhibitors among protease inhibitors-experienced patients: implications for tipranavir use.
Gallego O; de Mendoza C; Corral A; Barrios A; Soriano V
AIDS Patient Care STDS; 2005 Feb; 19(2):67-9. PubMed ID: 15716637
[No Abstract] [Full Text] [Related]
15. Oropharyngeal candidiasis in HIV-infected patients under treatment with protease inhibitors.
Migliorati CA; Birman EG; Cury AE
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2004 Sep; 98(3):301-10. PubMed ID: 15356467
[TBL] [Abstract][Full Text] [Related]
16. Response of feline immunodeficiency virus (FIV) to tipranavir may provide new clues for development of broad-based inhibitors of retroviral proteases acting on drug-resistant HIV-1.
Norelli S; El Daker S; D'Ostilio D; Mele F; Mancini F; Taglia F; Ruggieri A; Ciccozzi M; Cauda R; Ciervo A; Barreca ML; Pistello M; Bendinelli M; Savarino A
Curr HIV Res; 2008 Jun; 6(4):306-17. PubMed ID: 18691029
[TBL] [Abstract][Full Text] [Related]
17. Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen.
Ghosn J; Carosi G; Moreno S; Pokrovsky V; Lazzarin A; Pialoux G; Sanz-Moreno J; Balogh A; Vandeloise E; Biguenet S; Leleu G; Delfraissy JF
Antivir Ther; 2010; 15(7):993-1002. PubMed ID: 21041914
[TBL] [Abstract][Full Text] [Related]
18. Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro.
Johnson VA; Merrill DP; Chou TC; Hirsch MS
J Infect Dis; 1992 Nov; 166(5):1143-6. PubMed ID: 1328402
[TBL] [Abstract][Full Text] [Related]
19. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates.
De Meyer S; Azijn H; Surleraux D; Jochmans D; Tahri A; Pauwels R; Wigerinck P; de Béthune MP
Antimicrob Agents Chemother; 2005 Jun; 49(6):2314-21. PubMed ID: 15917527
[TBL] [Abstract][Full Text] [Related]
20. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting.
Harrigan PR; Hertogs K; Verbiest W; Pauwels R; Larder B; Kemp S; Bloor S; Yip B; Hogg R; Alexander C; Montaner JS
AIDS; 1999 Oct; 13(14):1863-71. PubMed ID: 10513644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
